Inflammatory Bowel Disease (IBD) in Mosul Hospital: A cross- Sectional Study - Analysis of Prevalence, Risk Factors, and Clinical Outcomes
Main Article Content
Abstract
Introduction: This study aimed to investigate the prevalence, risk factors, and clinical outcomes of Inflammatory Bowel Disease (IBD) in Mosul Hospital, Iraq, in 2022. Methods: A cross-sectional study design was used to collect data from patients diagnosed with IBD in Mosul Hospital. A questionnaire was used to collect demographic and clin- ical data, including risk factors, symptoms, and treatment outcomes. Data were analyzed using descriptive statistics and logistic regression. Results: The study included 150 participants, with a mean age of (42.5. ± years and 56% being male. Women were found to be less likely to know the type of Crohn’s disease compared to men. 58.7% of participants did not have any other diseases, while 41.3% had multiple diseases. The CH type was known for 56.8% of participants, and the average disease duration was 70.41 months, ranging from 2 to 360 months. Most participants (72.1%) did not have involvement in a particular place, while 27.9% did. All participants had known involvement. 81.8% of participants did not use drugs, while 18.2% did, with partial or unknown drug usage reported in 39 in- dividuals. Only 7.8% of participants had IBD in their family, while 92.2% did not. Most participants (95.2%) were smokers. Conclusion: The study highlights the need for increased awareness and early detection of IBD in Mosul Hospital. The identification of risk factors and symptoms can aid in the diagnosis and management of the disease. Further research is necessary to understand the underlying causes of IBD and to develop effective prevention and treatment strategies.
Downloads
Article Details
References
Dehghani T, Gholizadeh O, Daneshvar M, Nemati MM, Akbarzadeh S, Amini P, et al. Association Between Inflammatory Bowel Disease and Viral Infections. Current Microbiology. 2023;80(6):195. doi:10.1007/s00284-023-03305-0
Enaud R, Lamireau T. Differential Diagnosis of Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease: Springer; 2023. p. 217-28. doi:10.1007/978-3-031-14744-9_17
Swierczynski M, Makaro A, Grochowska A, Salaga M. Pharmacological approaches to treat intestinal pain. Expert Rev Clin Pharmacol. 2023;16(4):297-311. doi:10.1080/17512433.2023.2195626
Lenti MV, Scribano ML, Biancone L, Ciccocioppo R, Pugliese D, Pastorelli L, et al. Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease. Front Med (Lausanne). 2023;10:1031998. doi:10.3389/fmed.2023.1031998
Le Berre C, Danese S, Peyrin-Biroulet L. Can we change the natural course of inflammatory bowel disease? Therapeutic Advances in Gastroenterology. 2023;16:17562848231163118. doi:10.1177/17562848231163118
Grimsdottir S, Attauabi M, Dahl EK, Burisch J, Seidelin JB. Systematic review with meta-analysis: The impact of cancer treatments on the disease activity of inflammatory bowel diseases. J Crohns Colitis. 2023:jjad010. doi:10.1093/ecco-jcc/ jjad010
Lewandowski K, Kaniewska M, Więcek M, Szwarc P, Panufnik P, Tulewicz-Marti E, et al. Risk Factors for Osteoporosis among Patients with Inflammatory Bowel Disease-Do We Already Know Everything? Nutrients. 2023;15(5):1151. doi:10.3390/ nu15051151
Gold SL, Rabinowitz LG, Manning L, Keefer L, Rivera-Carrero W, Stanley S, et al. High Prevalence of Malnutrition and Micronutrient Deficiencies in Patients With Inflammatory Bowel Disease Early in Disease Course. Inflamm Bowel Dis. 2023;29(3):423-9. doi:10.1093/ibd/izac102
Vestergaard T, Julsgaard M, Røsok JF, Vestergaard SV, Helmig RB, Friedman S, et al. Predictors of disease activity during pregnancy in women with inflammatory bowel disease-a Danish cohort study. Alimentary Pharmacology & Therapeutics. 2023. doi:10.1111/apt.17378
Sonnenberg A, Genta RM. Case-control study of the concurrence of coeliac disease with inflammatory bowel disease. Aliment Pharmacol Ther. 2023;57(9):988-92. doi:10.1111/apt.17408
Jeong J, Walters TD, Huynh HQ, Lawrence S, Mack DR, Deslandres C, et al. Inflammatory Bowel Disease Among Canadian Children: Comparison Between Children of Non-European Descent and Children of European Descent. Inflammatory Bowel Diseases. 2023:izac276. doi:10.1093/ibd/ izac276
Burisch J, Zhao M, Odes S, De Cruz P, Vermeire S, Bernstein CN, et al. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2023;8(5):458-92. doi:10.1016/S2468-1253(23)00003-1
Degli Esposti L, Daperno M, Dovizio M, Franchi A, Sangiorgi D, Savarino EV, et al. A retrospective analysis of treatment patterns, drug discontinuation and healthcare costs in Crohn’s disease patients treated with biologics. Dig Liver Dis. 2023. doi:10.1016/j.dld.2023.04.010
Lee HH, Gweon T-G, Kang S-G, Jung SH, Lee K-M, Kang S-B. Assessment of Fatigue and Associated Factors in Patients with Inflammatory Bowel Disease: A Questionnaire-Based Study. Journal of Clinical Medicine. 2023;12(9):3116. doi:10.3390/jcm12093116
Malekzadeh MM, Vahedi H, Gohari K, Mehdipour P, Sepanlou SG, Ebrahimi Daryani N, et al. Emerging Epidemic of Inflammatory Bowel Disease in a Middle Income Country: A Nation-wide Study from Iran. Arch Iran Med. 2016;19(1):2-15.
Al-Hussaini A, El Mouzan M, Hasosah M, Al- Mehaidib A, K AL, Saadah OI, et al. Clinical Pattern of Early-Onset Inflammatory Bowel Disease in Saudi Arabia: A Multicenter National Study. Inflamm Bowel Dis. 2016;22(8):1961-70. doi:10.1097/MIB.0000000000000796
Kappelman MD, Rifas-Shiman SL, Kleinman K, Ollendorf D, Bousvaros A, Grand RJ, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5(12):1424-9. doi:10.1016/j.cgh.2007.07.012
Tsironi E, Feakins RM, Roberts CS, Rampton DS, Phil D. Incidence of inflammatory bowel disease is rising and abdominal tuberculosis is falling in Bangladeshis in East London, United Kingdom. Official journal of the American College of Gastroenterology| ACG. 2004;99(9):1749-55. doi:10.1111/j.1572-0241.2004.30445.x
Busingye D, Pollack A, Chidwick K. Prevalence of inflammatory bowel disease in the Australian general practice population: A cross-sectional study. PLoS One. 2021;16(5):e0252458.doi: 10.1371/journal.pone.0252458
Yang H, Li Y, Wu W, Sun Q, Zhang Y, Zhao W, et al. The incidence of inflammatory bowel disease in Northern China: a prospective population-based study. PLoS One. 2014;9(7):e101296. doi:10.1371/journal.pone.0101296
Bernstein KI, Promislow S, Carr R, Rawsthorne P, Walker JR, Bernstein CN. Information needs and preferences of recently diagnosed patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17(2):5908.doi:10.1002/ibd.21363
Guo L, Reich J, Groshek J, Farraye FA. Social Media Use in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22(5):1231-8. doi:10.1097/MIB.0000000000000713
Promislow S, Walker JR, Taheri M, Bernstein CN. How well does the Internet answer patients’ questions about inflammatory bowel disease? Canadian Journal of Gastroenterology. 2010;24(11):671-7. doi:10.1155/2010/957264